{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:46:01Z","timestamp":1792788361806,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.eplepsyres.2019.106218","type":"journal-article","created":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T20:20:25Z","timestamp":1571084425000},"page":"106218","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Pharmacokinetic interaction of brivaracetam on other antiepileptic drugs in adults with focal seizures: Pooled analysis of data from randomized clinical trials"],"prefix":"10.1016","volume":"158","author":[{"given":"Brian D.","family":"Moseley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Otoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovicus","family":"Staelens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armel","family":"Stockis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2019.106218_bib0005","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/epi.12433","article-title":"Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial","volume":"55","author":"Biton","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106218_bib0010","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.eplepsyres.2018.06.002","article-title":"Brivaracetam-induced elevation of carbamazepine epoxide levels: a post-hoc analysis from the clinical development program","volume":"145","author":"Brodie","year":"2018","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2019.106218_bib0015","series-title":"United States Prescribing Information","author":"Briviact","year":"2018"},{"issue":"Suppl. 1","key":"10.1016\/j.eplepsyres.2019.106218_bib0020","article-title":"In vitro pharmacokinetic profile of brivaracetam reveals low risk of drug-drug interaction and unrestricted brain permeability","volume":"15","author":"Chanteux","year":"2015","journal-title":"Epilepsy Curr."},{"key":"10.1016\/j.eplepsyres.2019.106218_bib0025","series-title":"The Treatment of Epilepsy","first-page":"418","article-title":"Brivaracetam","author":"D\u2019Souza","year":"2016"},{"key":"10.1016\/j.eplepsyres.2019.106218_bib0030","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1212\/WNL.0b013e3181ec7f7f","article-title":"Adjunctive brivaracetam for refractory partial-onset seizures. A randomized, controlled trial","volume":"75","author":"French","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2019.106218_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2005.01.005","article-title":"Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of data from randomized clinical trials","volume":"64","author":"Gidal","year":"2005","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2019.106218_bib0040","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejphar.2011.04.064","article-title":"Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties","volume":"664","author":"Gillard","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2019.106218_bib0045","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1517\/14656566.2014.922544","article-title":"Pharmacotherapy of focal epilepsy","volume":"15","author":"Iyer","year":"2014","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.eplepsyres.2019.106218_bib0050","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1111\/epi.13212","article-title":"A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures","volume":"56","author":"Klein","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106218_bib0055","series-title":"SAS System for Mixed Models","author":"Littel","year":"1996"},{"key":"10.1016\/j.eplepsyres.2019.106218_bib0060","article-title":"The effect of brivaracetam on the pharmacokinetics of phenytoin: in vivo, in vitro, and modeling studies [Abstract 2.207]","author":"Moseley","year":"2016","journal-title":"American Epilepsy Society Annual Meeting Dec 2\u20136, 2016"},{"key":"10.1016\/j.eplepsyres.2019.106218_bib0065","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1124\/dmd.112.045328","article-title":"Effect of gemfibrozil on the metabolism of brivaracetam in vitro and in human subjects","volume":"40","author":"Nicolas","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.eplepsyres.2019.106218_bib0070","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1111\/j.1528-1167.2007.01201.x","article-title":"Lack of pharmacokinetic interaction of levetiracetam on carbamazepine, valproic acid, topiramate, and lamotrigine in children with epilepsy","volume":"48","author":"Otoul","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106218_bib0075","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1474-4422(03)00409-5","article-title":"Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs","volume":"2","author":"Patsalos","year":"2003","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.eplepsyres.2019.106218_bib0080","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs \u2212 best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106218_bib0085","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s40262-013-0087-0","article-title":"Drug interactions with the newer antiepileptic drugs (AEDs)--part 1: pharmacokinetic and pharmacodynamic interactions between AEDs","volume":"52","author":"Patsalos","year":"2013","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.eplepsyres.2019.106218_bib0090","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/j.1528-1157.1990.tb05385.x","article-title":"Interaction of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine, with valproate: a pharmacokinetic study","volume":"31","author":"Pisani","year":"1990","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106218_bib0095","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1097\/00007691-199812000-00012","article-title":"Carbamazepine-10,11-epoxide in therapeutic drug monitoring","volume":"20","author":"Potter","year":"1998","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.eplepsyres.2019.106218_bib0100","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2125.2008.03158.x","article-title":"The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy males","volume":"66","author":"Rolan","year":"2008","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2019.106218_bib0105","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/epi.12432","article-title":"Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial","volume":"55","author":"Ryvlin","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106218_bib0110","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/j.1365-2125.2006.02829.x","article-title":"The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males","volume":"63","author":"Sargentini-Maier","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2019.106218_bib0115","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1124\/dmd.107.017129","article-title":"Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects","volume":"36","author":"Sargentini-Maier","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.eplepsyres.2019.106218_bib0120","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/jcph.761","article-title":"Brivaracetam population pharmacokinetics and exposure-response modeling in adult subjects with partial-onset seizures","volume":"56","author":"Schoemaker","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2019.106218_bib0125","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.eplepsyres.2015.03.003","article-title":"Brivaracetam and carbamazepine interaction in healthy subjects and in vitro","volume":"113","author":"Stockis","year":"2015","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2019.106218_bib0130","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.eplepsyres.2016.11.001","article-title":"Brivaracetam and carbamazepine interaction study in adult patients with epilepsy","volume":"128","author":"Stockis","year":"2016","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2019.106218_bib0135","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1124\/dmd.115.069161","article-title":"Effect of rifampin on the disposition of brivaracetam in human subjects: further insights into brivaracetam hydrolysis","volume":"44","author":"Stockis","year":"2016","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.eplepsyres.2019.106218_bib0140","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/00007691-199612000-00006","article-title":"Relationships between carbamazepine-diol, carbamazepine-epoxide, and carbamazepine total and free steady-state concentrations in epileptic patients: the influence of age, sex, and comedication","volume":"18","author":"Svinarov","year":"1996","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.eplepsyres.2019.106218_bib0145","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1528-1167.2012.03598.x","article-title":"Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial","volume":"54","author":"Van Paesschen","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106218_bib0150","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1684\/epd.2014.0714","article-title":"Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs","volume":"16","author":"Zaccara","year":"2014","journal-title":"Epileptic Disord."}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121119303511?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121119303511?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:41:58Z","timestamp":1760276518000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121119303511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":30,"alternative-id":["S0920121119303511"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2019.106218","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic interaction of brivaracetam on other antiepileptic drugs in adults with focal seizures: Pooled analysis of data from randomized clinical trials","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2019.106218","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106218"}}